ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "1b5b5b1f-715a-422b-b082-e2075eeb643d"}, "_deposit": {"id": "24750", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "24750"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00024750", "sets": ["501"]}, "author_link": ["73534", "73535", "73536", "73537", "73538", "73539", "73540", "73541", "73542", "73543"], "item_10_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2017-06", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "599", "bibliographicPageStart": "593", "bibliographicVolumeNumber": "22", "bibliographic_titles": [{"bibliographic_title": "International Journal of Clinical Oncology", "bibliographic_titleLang": "en"}]}]}, "item_10_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: Nedaplatin (NDP)-related hypersensitivity reactions (HSRs) trigger adverse clinical events. Prediction and prevention of NDP-HSRs are thus essential to minimize the risk and maximize the benefit of NDP therapy. However, the incidence of NDP-HSRs and the associated risk factors remain unclear. Methods: We retrospectively examined patients who received NDP monotherapy between April 2011 and July 2015 in Nagoya University Hospital. HSRs severity was defined according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE ver.4). Risk factors for NDP-HSRs were determined using multivariate logistic regression. Results: Of 111 patients who received NDP monotherapy, 90 (81%) were female; median age was 59 years (range, 29–78 years). Eighty-eight patients had gynecological cancer and 20 suffered from head and neck cancer. Eight of 111 patients (7.2%) experienced NDP-HSRs, six of which developed in the second NDP cycle. However, all patients with NDP-HSRs were treated with carboplatin (CBDCA) for more than three cycles. Grade 3 and 4 HSRs developed in 2 patients. NDP-HSRs were significantly associated with a history of CBDCA-HSRs (odds ratio 37.5, 95% confidence interval 5.38–262, p \u003c 0.001) and with the interval between NDP administration and the previous platinum treatment (odds ratio 13.9, 95% confidence interval 1.23–158, p = 0.034). Conclusion: The risk of NDP-HSRs increases in patients with a history of CBDCA-HSRs and in those administered NDP for more than 6 months after previous platinum treatment. Such individuals must be closely monitored if given NDP, even if they are expected to benefit from the treatment.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_10_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "DOI", "subitem_identifier_uri": "https://doi.org/10.1007/s10147-017-1091-4"}, {"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/26972"}]}, "item_10_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Springer", "subitem_publisher_language": "en"}]}, "item_10_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1007/s10147-017-1091-4", "subitem_relation_type_select": "DOI"}}]}, "item_10_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "The final publication is available at Springer via https://doi.org/10.1007/s10147-017-1091-4", "subitem_rights_language": "en"}]}, "item_10_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_10_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1341-9625", "subitem_source_identifier_type": "PISSN"}]}, "item_1615787544753": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kawarada, Yuki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "73534", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyazaki, Masayuki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "73535", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Itoh, Ayaka", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "73536", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Araki, Risa", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "73537", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Iwamizu, Hidetaka", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "73538", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kataoka, Tomomi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "73539", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kumakura, Yasuo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "73540", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ota, Akiko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "73541", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagai, Taku", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "73542", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamada, Kiyofumi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "73543", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-06-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "IJCO-D-16-00350_R1.pdf", "filesize": [{"value": "1000.0 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 1000000.0, "url": {"label": "IJCO-D-16-00350_R1.pdf ファイル公開:2018/06/01", "objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/24750/files/IJCO-D-16-00350_R1.pdf"}, "version_id": "26d8dbfd-60f6-4925-82db-d498c673ee84"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions", "subitem_title_language": "en"}]}, "item_type_id": "10", "owner": "1", "path": ["501"], "permalink_uri": "http://hdl.handle.net/2237/26972", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2017-09-07"}, "publish_date": "2017-09-07", "publish_status": "0", "recid": "24750", "relation": {}, "relation_version_is_last": true, "title": ["Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions"], "weko_shared_id": -1}
  1. C100 医学部/医学系研究科
  2. C100a 雑誌掲載論文
  3. 学術雑誌

Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions

http://hdl.handle.net/2237/26972
http://hdl.handle.net/2237/26972
9d17dbd5-2cdc-4031-8736-755eccb91aba
名前 / ファイル ライセンス アクション
IJCO-D-16-00350_R1.pdf IJCO-D-16-00350_R1.pdf ファイル公開:2018/06/01 (1000.0 kB)
Item type 学術雑誌論文 / Journal Article(1)
公開日 2017-09-07
タイトル
タイトル Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions
言語 en
著者 Kawarada, Yuki

× Kawarada, Yuki

WEKO 73534

en Kawarada, Yuki

Search repository
Miyazaki, Masayuki

× Miyazaki, Masayuki

WEKO 73535

en Miyazaki, Masayuki

Search repository
Itoh, Ayaka

× Itoh, Ayaka

WEKO 73536

en Itoh, Ayaka

Search repository
Araki, Risa

× Araki, Risa

WEKO 73537

en Araki, Risa

Search repository
Iwamizu, Hidetaka

× Iwamizu, Hidetaka

WEKO 73538

en Iwamizu, Hidetaka

Search repository
Kataoka, Tomomi

× Kataoka, Tomomi

WEKO 73539

en Kataoka, Tomomi

Search repository
Kumakura, Yasuo

× Kumakura, Yasuo

WEKO 73540

en Kumakura, Yasuo

Search repository
Ota, Akiko

× Ota, Akiko

WEKO 73541

en Ota, Akiko

Search repository
Nagai, Taku

× Nagai, Taku

WEKO 73542

en Nagai, Taku

Search repository
Yamada, Kiyofumi

× Yamada, Kiyofumi

WEKO 73543

en Yamada, Kiyofumi

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利
言語 en
権利情報 The final publication is available at Springer via https://doi.org/10.1007/s10147-017-1091-4
抄録
内容記述 Background: Nedaplatin (NDP)-related hypersensitivity reactions (HSRs) trigger adverse clinical events. Prediction and prevention of NDP-HSRs are thus essential to minimize the risk and maximize the benefit of NDP therapy. However, the incidence of NDP-HSRs and the associated risk factors remain unclear. Methods: We retrospectively examined patients who received NDP monotherapy between April 2011 and July 2015 in Nagoya University Hospital. HSRs severity was defined according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE ver.4). Risk factors for NDP-HSRs were determined using multivariate logistic regression. Results: Of 111 patients who received NDP monotherapy, 90 (81%) were female; median age was 59 years (range, 29–78 years). Eighty-eight patients had gynecological cancer and 20 suffered from head and neck cancer. Eight of 111 patients (7.2%) experienced NDP-HSRs, six of which developed in the second NDP cycle. However, all patients with NDP-HSRs were treated with carboplatin (CBDCA) for more than three cycles. Grade 3 and 4 HSRs developed in 2 patients. NDP-HSRs were significantly associated with a history of CBDCA-HSRs (odds ratio 37.5, 95% confidence interval 5.38–262, p < 0.001) and with the interval between NDP administration and the previous platinum treatment (odds ratio 13.9, 95% confidence interval 1.23–158, p = 0.034). Conclusion: The risk of NDP-HSRs increases in patients with a history of CBDCA-HSRs and in those administered NDP for more than 6 months after previous platinum treatment. Such individuals must be closely monitored if given NDP, even if they are expected to benefit from the treatment.
言語 en
内容記述タイプ Abstract
出版者
言語 en
出版者 Springer
言語
言語 eng
資源タイプ
資源タイプresource http://purl.org/coar/resource_type/c_6501
タイプ journal article
出版タイプ
出版タイプ AM
出版タイプResource http://purl.org/coar/version/c_ab4af688f83e57aa
DOI
関連タイプ isVersionOf
識別子タイプ DOI
関連識別子 https://doi.org/10.1007/s10147-017-1091-4
ISSN
収録物識別子タイプ PISSN
収録物識別子 1341-9625
書誌情報 en : International Journal of Clinical Oncology

巻 22, 号 3, p. 593-599, 発行日 2017-06
著者版フラグ
値 author
URI
識別子 https://doi.org/10.1007/s10147-017-1091-4
識別子タイプ DOI
URI
識別子 http://hdl.handle.net/2237/26972
識別子タイプ HDL
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 13:54:44.991343
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3